By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion's patented technology allows tumors to continuously signal their location and activity levels during treatment, revolutionizing the practice of radiation oncology.
With the use of a radio-labeled tracer called FDG, PET depicts the metabolic activity of tumors, causing them to “light up”. Alternative PET tracers can be used to identify other distinct biological characteristics of tumors such as hypoxia and cellular proliferation.
Combining PET with radiotherapy at the time of treatment has significant potential, allowing signals originating from tumors throughout the body to be harnessed directly during treatment delivery by the RefleXion System.
Prior to the RefleXion System, PET had not been incorporated into treatment delivery because it takes minutes to generate a reasonable quality image, making it unsuitable to compensate for motion caused by respiration and other bodily functions.
Latest funding size
Time since last funding
|Venrock, Sofinnova Partners, Pfizer Venture Investments, Johnson & Johnson Innovation, KCK|